Pozen MT-100 Migraine Combo Goes To Advisory Committee August 4
This article was originally published in The Pink Sheet Daily
Executive Summary
Tardive dyskinesia and cardiovascular issues are likely discussion topics for FDA’s Peripheral & Central Nervous System Drugs Advisory Committe. Treatment was to be reviewed by the committee in May but was postponed due to “scheduling conflicts.”
You may also be interested in...
Pozen Migraine Agent Advisory Cmte. Postponed; August Meeting Possible
Tardive dyskinesia risk with MT-100, the metoclopromide/naproxen combination product for migraine, continues to be the focus of a committee meeting, Pozen says. NDA filing for sumatriptan/naproxen migraine product Trexima is planned for the third quarter.
Pozen’s Migraine Agent To Be Focus Of FDA Advisory Committee Review
Naproxen/metoclopramide combination is expected to be reviewed by the Peripheral & Central Nervous System Drugs Advisory Committee May 4. Potential risk of tardive dyskinesia is expected to be discussed. FDA deemed MT-100 “not approvable” earlier this year.
Pozen Migraine Combo “Not Approvable”; Company Seeks Meeting With FDA
Naproxen/metoclopramide fixed-dose combo did not meet efficacy endpoints in second study, FDA letter says. Agency also questions potential risk of tardive dyskinesia and carcinogenicity in denying approval of MT-100.